Table I.
Patient Characteristics
| Characteristic | Number (%) |
|---|---|
| Age (years) | |
| Median (range) | 62 (38–78) |
| Gender | |
| Males | 18 (46.2%) |
| Females | 21 (53.8%) |
| Baseline ECOG performance status | |
| 0 | 17 (43.6%) |
| 1 | 17 (43.6%) |
| 2 | 5 (12.8%) |
| Histological sub-classification | |
| Adenocarcinoma | 29 (74.4%) |
| Bronchoalveolar carcinoma | 4 (10.3%) |
| Squamous cell carcinoma | 5 (12.8%) |
| Large cell carcinoma | 1 (2.5%) |
| Mutational status | |
| No mutation | 20 (51.3%) |
| EGFR mutation | 7 (17.9%) |
| KRAS mutation | 3 (7.7%) |
| No information available | 9 (23.1%) |
| Smoking status | |
| Non-smoker (0.0 pack-years) | 14 (35.9%) |
| Previous light smoker (0.1–10 pack-years) | 4 (10.2%) |
| Previous heavy smoker (>10 pack-years) | 5 (12.8%) |
| Current smoker | 13 (33.4%) |
| No data available | 3 (7.7%) |
| Radiation therapy | |
| No radiation therapy | 19 (48.8%) |
| Before starting erlotinib [mean total dose ± standard deviation] | 8 (20.5%) [40.4 Gy ± 8.8 ] |
| During erlotinib treatment [mean total dose ± standard deviation] | 7 (17.9%) [58.6 Gy ± 32.9] |
| After erlotinib treatment [mean total dose ± standard deviation] | 5 (12.8%) [64.4 Gy ± 31.7] |
| Survival during the first scheduled 12 months | |
| Died | 24 (61.5%) |
| Overall survival/daysa, medianb (range) | 165 (10–429) |
ECOG Eastern Cooperative Oncology Group
aOverall survival was defined as the length of time the patients lived after starting erlotinib therapy
bBased on Kaplan-Meier estimate